scholarly article | Q13442814 |
P356 | DOI | 10.1515/AIHT-2016-67-2754 |
P698 | PubMed publication ID | 27092633 |
P50 | author | Aleksandar J Dimovski | Q91153321 |
P2093 | author name string | Valon Krasniqi | |
Nada Božina | |||
Iva Klarica Domjanović | |||
Ivan Bilić | |||
P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
Epoxyeicosatrienoic acid pathway in human health and diseases | Q28275759 | ||
Pharmacogenetics: from bench to byte--an update of guidelines | Q34171192 | ||
Chiral inversion of 2-arylpropionyl-CoA esters by human α-methylacyl-CoA racemase 1A (P504S)--a potential mechanism for the anti-cancer effects of ibuprofen. | Q34187468 | ||
Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. | Q51769708 | ||
Interaction of γ-glutamyltranspeptidase with ibuprofen-S-acyl-glutathione in vitro and in vivo in human. | Q53140524 | ||
Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro. | Q53232379 | ||
CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations. | Q54274861 | ||
Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms | Q58193493 | ||
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects | Q34307589 | ||
Clinical pharmacokinetics of ibuprofen. The first 30 years | Q34461383 | ||
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies | Q35003605 | ||
Acyl glucuronide reactivity in perspective: biological consequences | Q35103665 | ||
The metabolism of diclofenac--enzymology and toxicology perspectives | Q35181095 | ||
The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. | Q35827277 | ||
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance | Q36131028 | ||
The apical conjugate efflux pump ABCC2 (MRP2). | Q36539096 | ||
Nonsteroidal anti-inflammatory drug-induced hepatotoxicity | Q36920992 | ||
Global variation in CYP2C8-CYP2C9 functional haplotypes | Q37434738 | ||
Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk | Q37542607 | ||
Personalized therapy in pain management: where do we stand? | Q37760955 | ||
Genetic polymorphism and toxicology--with emphasis on cytochrome p450. | Q37819666 | ||
Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport | Q39578741 | ||
Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. | Q41100709 | ||
Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly | Q42279636 | ||
Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. | Q42918844 | ||
Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions | Q43066596 | ||
Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters | Q43189634 | ||
Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac | Q43569654 | ||
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro | Q43877657 | ||
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. | Q44085582 | ||
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity | Q44880285 | ||
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms | Q45004302 | ||
Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. | Q45990596 | ||
Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro | Q46372792 | ||
Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers | Q46434971 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P921 | main subject | Diclofenac | Q244408 |
P304 | page(s) | 1-8 | |
P577 | publication date | 2016-03-01 | |
P1433 | published in | Archives of Industrial Hygiene and Toxikology | Q15724434 |
P1476 | title | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity | |
P478 | volume | 67 |
Q58697719 | A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines |
Q38717713 | Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. |
Q40983323 | Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9. |
Q49612685 | Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. |
Q64953662 | Ibuprofen nanocrystals developed by 22 factorial design experiment: A new approach for poorly water-soluble drugs. |
Q64057344 | Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population |
Q92119375 | Optimising migraine treatment: from drug-drug interactions to personalized medicine |
Q58122665 | Simulated Microgravity Altered the Metabolism of Loureirin B and the Expression of Major Cytochrome P450 in Liver of Rats |
Search more.